Filing Analysis
Plus Therapeutics, Inc. has regained compliance with Nasdaq's minimum bid price requirement following a significant 1-for-25 reverse stock split. The company received official notification from Nasdaq on April 20, 2026, confirming it met the requirements of Listing Rule 5550(a)(2).
Red Flags
- Implementation of a massive 1-for-25 reverse stock split to maintain listing.
- History of non-compliance with Nasdaq minimum bid price requirements.
Key Facts
- Received Nasdaq Notification Letter on April 20, 2026, confirming compliance.
- The company regained compliance with the $1.00 minimum bid price requirement.
- Compliance was achieved through a 1-for-25 reverse stock split effective April 2, 2026.
- The company continues to be listed on The Nasdaq Capital Market under the symbol PSTV.
Plus Therapeutics, Inc. has appointed Dr. Eric J. Daniels as Chief Development Officer, effective April 20, 2026. Dr. Daniels, who previously served as CDO of Kiora Pharmaceuticals, will be responsible for the development and regulatory approval of the company’s pharmaceutical pipeline.
Key Facts
- Dr. Eric J. Daniels appointed as Chief Development Officer effective April 20, 2026.
- Initial annual base salary set at $460,000 with a 40% annual target bonus.
- Inducement equity grant includes 20,000 stock options and 20,000 restricted stock units (RSUs).
- Dr. Daniels previously held leadership roles at Kiora Pharmaceuticals (NASDAQ: KPRX), Bayon Therapeutics, and OccuRx Pty Ltd.
- Severance package includes 12 months of base salary, target bonus, and 9 months of accelerated equity vesting in the event of involuntary termination.
Plus Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead drug candidate, REYOBIQ™ (rhenium Re186 obisbemeda), for the treatment of pediatric malignant gliomas.
Key Facts
- The FDA granted Orphan Drug Designation (ODD) on April 8, 2026.
- The designation is for REYOBIQ™ (rhenium Re186 obisbemeda) specifically for pediatric malignant gliomas.
- The filing includes a press release (Exhibit 99.1) detailing the regulatory milestone.
- Plus Therapeutics is headquartered in Houston, Texas, and trades on the Nasdaq Capital Market under the symbol PSTV.
Plus Therapeutics, Inc. implemented a 1-for-25 reverse stock split effective April 2, 2026, to consolidate its share count from approximately 171.6 million to 6.9 million shares. The split did not reduce the number of authorized shares, significantly increasing the company's capacity for future equity issuance and potential dilution.
Red Flags
- Reverse stock split (1-for-25) is a significant consolidation often used to artificially inflate share price for exchange compliance.
- Authorized shares were not reduced in proportion to the split, creating a massive potential for future shareholder dilution.
Key Facts
- Reverse stock split ratio of 1-for-25 effective as of 12:01 a.m. on April 2, 2026.
- Common stock outstanding reduced from approximately 171,550,698 shares to approximately 6,862,027 shares.
- The number of authorized shares of common stock was not reduced, increasing the pool of shares available for future issuance.
- New CUSIP number for the common stock is 72941H806.
- Fractional shares will be compensated via cash payments based on fair market value.
Plus Therapeutics announced the appointment of Ronald A. Andrews to its Board of Directors, effective March 20, 2026, filling a vacancy created by the resignation of Dr. Robert Lenk. Mr. Andrews is an industry veteran with over 35 years of experience in diagnostics and molecular diagnostics, including leadership roles at Thermo Fisher Scientific and Oncocyte Inc.
Key Facts
- Ronald A. Andrews appointed to the Board and Nominating and Corporate Governance Committee on March 20, 2026.
- Dr. Robert Lenk resigned from the Board on March 20, 2026, with no reported disagreements regarding company operations.
- Mr. Andrews previously served as President and CEO of Oncocyte Inc. (NASDAQ: OCX) and President of the Genetic Sciences Division at Thermo Fisher Scientific (NASDAQ: TMO).
- Mr. Andrews is determined to be an 'independent director' under Nasdaq listing standards.
Plus Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on May 14, 2026. Due to the meeting being scheduled more than 30 days from the anniversary of the prior year's meeting, the company has established new deadlines for shareholder proposals and director nominations.
Key Facts
- The 2026 Annual Meeting of Stockholders is scheduled for May 14, 2026, at 9:00 a.m. ET.
- The record date for stockholders entitled to vote is March 18, 2026.
- The deadline for submitting stockholder proposals under Rule 14a-8 is March 22, 2026.
- The deadline for director nominations or other business under the Company's Bylaws is March 22, 2026, at 5:00 p.m. ET.
- The meeting will be conducted in a virtual-only format.
Plus Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The filing serves as a formal vehicle to furnish the earnings press release and provide recent corporate updates.
Key Facts
- Financial results reported for Q4 and fiscal year ended December 31, 2025
- Filing date and earliest event date of March 12, 2026
- Information furnished under Item 2.02 (Results of Operations and Financial Condition)
- Included Exhibit 99.1: Press Release Announcing Financial Results